As European markets rebound, with the STOXX Europe 600 Index climbing 3.93% and major indices like Italy’s FTSE MIB and the UK’s FTSE 100 showing significant gains, investor sentiment has been buoyed by the ECB's rate cuts and a delay in higher tariffs by President Trump. In this environment of cautious optimism, growth companies with high insider ownership can be attractive as they often indicate confidence from those closest to the business, potentially aligning well with market conditions that favor strategic long-term investments.
Name | Insider Ownership | Earnings Growth |
Pharma Mar (BME:PHM) | 11.8% | 40.1% |
Vow (OB:VOW) | 13.1% | 111.2% |
Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
Elicera Therapeutics (OM:ELIC) | 20.5% | 97.2% |
CD Projekt (WSE:CDR) | 29.7% | 37.4% |
Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
Lokotech Group (OB:LOKO) | 13.6% | 58.1% |
Ortoma (OM:ORT B) | 27.7% | 68.6% |
Nordic Halibut (OB:NOHAL) | 29.7% | 60.7% |
Xbrane Biopharma (OM:XBRANE) | 20% | 82.7% |
Click here to see the full list of 215 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Let's dive into some prime choices out of the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Norbit ASA offers technology solutions across various industries and has a market cap of NOK8.34 billion.
Operations: The company's revenue is derived from three main segments: Oceans (NOK743.90 million), Connectivity (NOK515.70 million), and Product Innovation and Realization (PIR) (NOK543.10 million).
Insider Ownership: 13.2%
Earnings Growth Forecast: 26.1% p.a.
Norbit ASA demonstrates strong growth potential, with earnings expected to grow significantly at 26.1% annually, outpacing the Norwegian market. Recent guidance for 2025 targets revenues between NOK 2.2 billion and NOK 2.3 billion, with improved EBIT margins supported by robust demand across segments like Oceans and PIR. The company has also secured substantial orders in the defence sector worth approximately NOK 260 million, enhancing its growth outlook despite seasonal fluctuations and currency impacts.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BICO Group AB (publ) offers hardware, laboratory automation, and software solutions across North America, Europe, Asia, and internationally with a market cap of SEK2.54 billion.
Operations: The company's revenue segments include Bioprinting with SEK369.30 million, Lab Automation at SEK571.60 million, and Life Science Solutions generating SEK1.01 billion.
Insider Ownership: 24.9%
Earnings Growth Forecast: 54.5% p.a.
BICO Group's recent financial performance shows a turnaround, with net income reaching SEK 346.8 million in Q4 2024 compared to a significant loss the previous year. Despite trading below its estimated fair value and showing good relative value compared to peers, BICO faces challenges with high share price volatility and low forecasted return on equity at 2.9%. Revenue growth of 7.2% annually is expected, outpacing the Swedish market but remaining below high-growth benchmarks.
Simply Wall St Growth Rating: ★★★★★★
Overview: Bonesupport Holding AB is an orthobiologics company that develops and sells injectable bio-ceramic bone graft substitutes globally, with a market cap of SEK20.50 billion.
Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, amounting to SEK898.73 million.
Insider Ownership: 10.1%
Earnings Growth Forecast: 48.1% p.a.
Bonesupport Holding's growth trajectory is underscored by its high expected revenue growth of 29.5% annually, surpassing the Swedish market's average. Despite a decline in profit margins from 41.5% to 14.9%, its earnings are forecasted to grow significantly at 48.1% per year, outpacing the market average of 13.1%. The company recently reported strong sales figures and is advancing its product pipeline with CERAMENT® V seeking FDA approval, enhancing its competitive position in bone infection management solutions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OB:NORBT OM:BICO and OM:BONEX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。